Project Grant P01AI189362
Award Date 8/1/25
Completion Date 6/30/30
Dollars Obligated $4.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement to Weill Medical College of Cornell University on August 12, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this project is to identify an optimal prime-boost immunization strategy to guide antibody maturation towards broad neutralization of HIV in early life. The project aims to: 1) Compare sequential versus simultaneous...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $791,661 to Duke University to develop a vaccine strategy for HIV-1. The key objectives are to optimize a vaccine delivery platform using integrase-defective lentiviral vectors (IDLVs) to persistently express HIV-1 envelope trimers and Gag antigen. The goal is to elicit durable neutralizing antibody and T-cell...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This federal Project Grant award of $190,944, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to investigate the dynamics and formation of B cell immune memory in human vaccination. The research aims to systematically analyze human B cell, plasma cell, and antibody responses after HIV vaccination, and to dissect the mechanisms by which novel vaccine adjuvants like 3M-052-AF...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop a multivalent mRNA HIV vaccine that can elicit broadly neutralizing antibodies targeting the conserved envelope (Env) region of recently circulating subtype C HIV strains. The central hypothesis is that priming with a single Env immunogen followed by boosting with a multivalent Env immunogen set...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,486 to the Scripps Research Institute to develop soluble and membrane-bound immunogens that can shepherd the maturation of broadly neutralizing antibodies (bnAbs) targeting the highly conserved membrane proximal external region (MPER) of the HIV-1 envelope protein. The goal is to advance the quest for a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, Davis. This funding will support a collaborative HIV vaccine research program, referred to as OPTI-FLIP, that aims to develop a vaccine regimen leveraging cooperative interactions between antibody and T-cell immune responses. The key research activities funded under this grant...